American Academy

Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights

Retrieved on: 
Monday, May 9, 2022

Additional data from the RESCUE-ALS open-label extension were presented in a late breaker session at the American Academy of Neurology Annual Meeting (April 2022).

Key Points: 
  • Additional data from the RESCUE-ALS open-label extension were presented in a late breaker session at the American Academy of Neurology Annual Meeting (April 2022).
  • Unblinded data from the VISIONARY-MS Phase 2 clinical trial data are targeted for the third quarter of 2022.
  • Clene expects that its cash as of March 31, 2022, will be sufficient to fund its operations into the second quarter of 2023.
  • Research and development expenses were $8.6 million for the quarter ended March 31, 2022, compared to $6.3 million for the same period in 2021.

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022

CAMBRIDGE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2022.

Key Points: 
  • (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today provided a business update and reported financial results for the first quarter of 2022.
  • Additionally, we plan to begin dosing patients in REACH, our Phase 3 trial of losmapimod in FSHD, in the second quarter.
  • Open next dose cohort in Phase 1b trial in people with sickle cell disease in the second quarter of 2022.
  • ET to discuss the Companys first quarter 2022 recent business highlights and financial results.

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022

ET

Key Points: 
  • ET
    DUBLIN, Ireland, May 09, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update, and announced its financial results for the first quarter ended March 31, 2022.
  • R&D expenses were $7.0 million in the quarter ended March 31, 2022, compared to $3.9 million for the same period in 2021.
  • SG&A expenses were $21.6 million in the quarter ended March 31, 2022, compared to $11.0 million for the same period in 2021.
  • The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

Local Eye Center South Dr. Harsha Sen Published as National Expert on Complex Retina Disorders

Retrieved on: 
Friday, May 6, 2022

The part of the retina that is affected by retinoschisis can lead to detachment of the entire retina and loss of vision.

Key Points: 
  • The part of the retina that is affected by retinoschisis can lead to detachment of the entire retina and loss of vision.
  • Dr. Sen was recruited to write the chapter based on his surgical experience and ties to the Duke University retinal ophthalmology community.
  • Dr. Sen joined Eye Center South four years ago as a retinal surgeon in Dothan, AL.
  • A year later, he was named Medical Director for all Eye Center South locations in Alabama, Florida, and Georgia.

STREET NAMED IN HONOR OF LEGENDARY BALLET DANCER AND ARTS EDUCATION LUMINARY JACQUES D'AMBOISE

Retrieved on: 
Friday, May 6, 2022

NEW YORK, May 6, 2022 /PRNewswire/ -- A street in New York City has been named in commemoration of the life and achievements of Jacques d'Amboise, legendary ballet dancer and founder of the arts education organization National Dance Institute (NDI). The northwest corner of West 64th Street and Columbus Avenue in front of New York's Lincoln Center now displays the name Jacques d'Amboise Place. The ceremony took place adjacent to New York City Ballet where Mr. d'Amboise called home for 35 years. Mr. d'Amboise passed away just one year ago, leaving a legacy of giving children everywhere access to the joy and transformative power of the arts through NDI, the organization he founded 46 years ago.

Key Points: 
  • NEW YORK, May 6, 2022 /PRNewswire/ -- A street in New York City has been named in commemoration of the life and achievements of Jacques d'Amboise, legendary ballet dancer and founder of the arts education organization National Dance Institute (NDI).
  • The northwest corner of West 64th Street and Columbus Avenue in front of New York's Lincoln Center now displays the name Jacques d'Amboise Place.
  • "Jacques d'Amboise leaves behind a wonderful legacy that inspires artists to continue Manhattan's prominence as a global center of music, dance, theater, and the visual arts.
  • The Jacques d'Amboise Legacy Fund has been established to support artistic endeavors that honor his vision, creativity, and commitment to arts education.

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022

LP659, an oral, selective, centrally acting S1P receptor modulator targeting multiple neurological diseases, is currently in IND-enabling studies with IND application submission to the FDA expected in the fourth quarter of 2022.

Key Points: 
  • LP659, an oral, selective, centrally acting S1P receptor modulator targeting multiple neurological diseases, is currently in IND-enabling studies with IND application submission to the FDA expected in the fourth quarter of 2022.
  • In March 2022, Dr. Randall Kaye joined the Company as Chief Medical Officer.
  • First Quarter 2022 Financial Results:
    At March 31, 2022, Longboards cash, cash equivalents and short-term investments were approximately $96.1 million.
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Anika Reports First Quarter Fiscal 2022 Financial Results

Retrieved on: 
Thursday, May 5, 2022

BEDFORD, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2022.

Key Points: 
  • BEDFORD, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today reported financial results for its first quarter ended March 31, 2022.
  • Anika is off to a strong start in 2022 in spite of macroeconomic headwinds, Cheryl R. Blanchard, Ph.D., Anikas President and CEO, commented.
  • Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Companys reported financial results prepared in accordance with GAAP.
  • ANIKA, ANIKA THERAPEUTICS, OVOMOTION, TACTOSET, WRISTMOTION and the Anika logo are registered trademarks of Anika Therapeutics, Inc. or its subsidiaries.

Sensus Healthcare First Quarter 2022 Financial Results Feature Revenue Growth of 237%

Retrieved on: 
Thursday, May 5, 2022

BOCA RATON, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2022.

Key Points: 
  • Revenues for the first quarter of 2022 were $10.3 million, compared with $3.1 million for the first quarter of 2021.
  • Cost of sales for the first quarter of 2022 was $3.2 million, compared with $1.5 million for the prior-year quarter.
  • Research and development expense for the first quarter of 2022 was $0.7 million, unchanged from the prior-year first quarter.
  • Adjusted EBITDA for the first quarter of 2022 was $16.9 million, compared with $(0.8) million for the first quarter of 2021.

Anne Truong, M.D. Invited to Speak at the 2022 American Academy of Orthopedic Medicine Annual Conference

Retrieved on: 
Thursday, May 5, 2022

FREDERICKSBURG. Va., May 5, 2022 /PRNewswire-PRWeb/ -- Truong Rehabilitation Center is pleased to announce that its founder and principal, Anne Truong, M. D. will speak on May 5, 2022 at the American Academy of Orthopedic Medicine (AAOM) Annual Conference in Denver, Colorado. Dr. Truong will cover Sexual Health Treatment and Hormones for Regenerative Medicine. In addition, on May 7 at AAOM, Dr. Truong will conduct a workshop on Marketing Your Regenerative Medicine Practice.

Key Points: 
  • Va., May 5, 2022 /PRNewswire-PRWeb/ -- Truong Rehabilitation Center is pleased to announce that its founder and principal, Anne Truong, M. D. will speak on May 5, 2022 at the American Academy of Orthopedic Medicine (AAOM) Annual Conference in Denver, Colorado.
  • In addition, on May 7 at AAOM, Dr. Truong will conduct a workshop on Marketing Your Regenerative Medicine Practice.
  • The AAOM Annual Conference is a three-day international event that unites physicians, researchers, and medical providers dedicated to regenerative interventional orthopedic medical care.
  • To learn more about Truong Rehabilitation Center and Anne Truong, M.D., please visit truongrehab.com.

HOYA Vision Care Releases Results of First of its Kind Six-Year MiYOSMART Spectacle Lens Follow-up Clinical Study

Retrieved on: 
Thursday, May 5, 2022

BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care, a leader in optical technology innovation, shared the results of a six-year follow-up clinical study on its award winning MiYOSMART spectacle lens with Defocus Incorporated Multiple Segments (D.I.M.S.) Technology at the Association for Research in Vision and Ophthalmology (ARVO) 2022 conference in Denver, Colorado in the U.S. The findings, of the longest study on a myopia management spectacle lens, were shared by Professor Carly Lam from the Centre for Myopia Research at The Hong Kong Polytechnic University who conducted the research. 

Key Points: 
  • BANGKOK, May 5, 2022 /PRNewswire/ -- HOYA Vision Care , a leader in optical technology innovation, sharedthe results of a six-year follow-up clinical study on its award winning MiYOSMART spectacle lens with Defocus Incorporated Multiple Segments (D.I.M.S.)
  • The results of the six-year clinical tudy conducted on 90 children in Asia looked at the progression of myopia in children who wore the HOYA Vision Care's MiYOSMART spectacle lens.
  • The findings of the six-year, long-term follow-up study proved the MiYOSMART spectacle lens myopia control effect is sustained over time for children wearing the lens.
  • "This six-year follow-up clinical study on the MiYOSMART spectacle lens, the longest study conducted on a myopia management spectacle lens ever, shows the myopia control effects are sustainable over time which is very exciting news," said Natalia Vlasak, Global head of Medical and Scientific Affairs at HOYA Vision Care.